Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 269-2813, Iss. 10, 2015-11 ,pp. : 1182-1191

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hepatocellular carcinoma risk in HBeAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. 2, 2015-02 ,pp. : 120-127

John Wiley & Sons Inc

Access to resources Recommend Favorite

P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction?

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 50-50

John Wiley & Sons Inc

Access to resources Recommend Favorite

On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 5, 2015-05 ,pp. : 1540-1548

John Wiley & Sons Inc

Access to resources Recommend Favorite

P042: Hepatitis B surface proteins (SHBs, LHBs and MHBs) decline after stopping of nucleos(t)ide analogue therapy in HBeAg‐negative patients

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 40-40

John Wiley & Sons Inc

Access to resources Recommend Favorite